Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-8 Years Apart

Trial Profile

Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-8 Years Apart

Suspended
Phase of Trial: Phase III

Latest Information Update: 31 May 2017

At a glance

  • Drugs Fexapotide (Primary)
  • Indications Benign prostatic hyperplasia
  • Focus Adverse reactions; Registrational
  • Most Recent Events

    • 31 May 2017 Results of pooled analysis of data from phase III trials (NX02-0017, NX02-0018, NX02-0020 and NX02-0022) evaluating standardized Sexual Function Questionnaire (SFQ) published in a Nymox Pharmaceutical Corporation media release.
    • 29 Nov 2016 Results of pooled analysis of data from phase 3 trials (NX02-0017, NX02-0018, NX02-0020 and NX02-0022) published in a Nymox Pharmaceutical Corporation.
    • 11 Oct 2016 Long-term results from this and another trial (CTP 700198473) published in a Nymox Pharmaceutical Corporation media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top